Genrui is pleased to announce that selected Specific Protein assays used on the PA240 and PA480 Fully Automated Specific Protein Analyzers have successfully completed the 2026 External Quality Assessment (EQA) organized by the National Center for Clinical Laboratories (NCCL), China.
The NCCL EQA program is one of China's national external quality assessment schemes, designed to evaluate laboratory testing performance through interlaboratory comparison using standardized specimens. Successful participation demonstrates the analytical accuracy, consistency, and robustness of participating testing systems.
The following Genrui Specific Protein assay categories were successfully evaluated:
✓ Specific Proteins (KAP, LAM, CR, RF, IgG, etc.)
✓ Urine Protein Markers
✓ Glycated Hemoglobin (HbA1c)
Participation in an independent external quality assessment program provides objective verification of analytical performance under routine laboratory conditions. The successful results further demonstrate the reliability, consistency, and quality of Genrui's nephelometry-based specific protein testing solution.
Backed by a comprehensive quality management system and continuous innovation, the PA240 and PA480 deliver dependable results that laboratories can trust for routine clinical testing.
Genrui remains committed to providing laboratories worldwide with high-quality diagnostic solutions that support standardized testing and better patient care.
